Oxymetazoline Can Shorten the Time Required for a Bronchoscope to Reach the Vocal Cords in Patients With Turbinate Hypertrophy.

IF 1.9 4区医学 Q2 OTORHINOLARYNGOLOGY

Clinical Otolaryngology Pub Date : 2026-09-01 Epub Date: 2026-06-26 DOI:10.1111/coa.70118

Jie Zhang, Fanliang Meng

{"title":"Oxymetazoline Can Shorten the Time Required for a Bronchoscope to Reach the Vocal Cords in Patients With Turbinate Hypertrophy.","authors":"Jie Zhang, Fanliang Meng","doi":"10.1111/coa.70118","DOIUrl":null,"url":null,"abstract":"Objectives: This study aims to investigate the effects of oxymetazoline on the time required for the bronchoscope to reach the vocal cords, nasal manipulation difficulty during bronchoscopy, nasal mucosal injury, and patient-reported pain in individuals with turbinate hypertrophy undergoing bronchoscopic examination.Materials and methods: This prospective, double-blinded, randomised controlled trial enrolled 240 patients with turbinate hypertrophy (November 2023 to July 2024), randomised into oxymetazoline, saline, and blank control groups (n = 80 each). The primary outcome was bronchoscope-to-vocal-cords time. Secondary outcomes included operator-assessed nasal passage ease (negotiation visual analog scale [VAS]), assistant-evaluated facial pain (Facial Pain Scale), patient-reported nasal pain (Pain VAS), operator-rated mucosal trauma (Trauma VAS) and hemodynamic parameters.Results: The oxymetazoline group demonstrated significantly shorter bronchoscope-to-vocal-cords time compared to the saline group (44.00 s [41.00-47.00] vs. 52.00 s [50.00-58.00], p < 0.001), improved nasal passage ease (negotiation VAS: 3.00 [2.00-4.00] vs. 5.00 [4.00-6.00], p < 0.001), and reduced mucosal trauma (Trauma VAS: 7.00 [6.00-8.00] vs. 9.00 [8.00-9.00], p < 0.001). Patients receiving oxymetazoline reported lower nasal pain scores (assistant-assessed: 4.00 [3.00-5.00] vs. 5.00 [5.00-6.00]; patient-reported: 4.00 [3.00-4.75] vs. 5.50 [5.00-6.00], both p < 0.001).Conclusion: Oxymetazoline optimises bronchoscopy in turbinate hypertrophy patients by shortening procedural time, easing nasal passage, mitigating mucosal injury, and alleviating pain. This trial is registered at chictr.org.cn (ChiCTR2300077642).","PeriodicalId":10431,"journal":{"name":"Clinical Otolaryngology","volume":" ","pages":"770-775"},"PeriodicalIF":1.9000,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13432570/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Otolaryngology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/coa.70118","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/6/26 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"OTORHINOLARYNGOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objectives: This study aims to investigate the effects of oxymetazoline on the time required for the bronchoscope to reach the vocal cords, nasal manipulation difficulty during bronchoscopy, nasal mucosal injury, and patient-reported pain in individuals with turbinate hypertrophy undergoing bronchoscopic examination.

Materials and methods: This prospective, double-blinded, randomised controlled trial enrolled 240 patients with turbinate hypertrophy (November 2023 to July 2024), randomised into oxymetazoline, saline, and blank control groups (n = 80 each). The primary outcome was bronchoscope-to-vocal-cords time. Secondary outcomes included operator-assessed nasal passage ease (negotiation visual analog scale [VAS]), assistant-evaluated facial pain (Facial Pain Scale), patient-reported nasal pain (Pain VAS), operator-rated mucosal trauma (Trauma VAS) and hemodynamic parameters.

Results: The oxymetazoline group demonstrated significantly shorter bronchoscope-to-vocal-cords time compared to the saline group (44.00 s [41.00-47.00] vs. 52.00 s [50.00-58.00], p < 0.001), improved nasal passage ease (negotiation VAS: 3.00 [2.00-4.00] vs. 5.00 [4.00-6.00], p < 0.001), and reduced mucosal trauma (Trauma VAS: 7.00 [6.00-8.00] vs. 9.00 [8.00-9.00], p < 0.001). Patients receiving oxymetazoline reported lower nasal pain scores (assistant-assessed: 4.00 [3.00-5.00] vs. 5.00 [5.00-6.00]; patient-reported: 4.00 [3.00-4.75] vs. 5.50 [5.00-6.00], both p < 0.001).

Conclusion: Oxymetazoline optimises bronchoscopy in turbinate hypertrophy patients by shortening procedural time, easing nasal passage, mitigating mucosal injury, and alleviating pain. This trial is registered at chictr.org.cn (ChiCTR2300077642).

查看原文本刊更多论文

氧苄唑啉可以缩短鼻甲肥大患者支气管镜到达声带所需的时间。

目的：本研究旨在探讨氧美唑啉对支气管镜到达声带所需时间、支气管镜检查时鼻腔操作困难、鼻黏膜损伤和鼻甲肥大患者接受支气管镜检查时报告的疼痛的影响。材料和方法：本前瞻性、双盲、随机对照试验纳入240例鼻甲肥大患者（2023年11月至2024年7月），随机分为羟甲基唑啉组、生理盐水组和空白对照组（各80例）。主要结果是支气管镜到声带的时间。次要结局包括术者评估的鼻腔通道通畅程度（协商视觉模拟量表[VAS]）、辅助评估的面部疼痛（面部疼痛量表）、患者报告的鼻腔疼痛（疼痛VAS）、术者评估的粘膜损伤（创伤VAS）和血流动力学参数。结果：氧美唑啉组支气管镜到声带的时间明显短于生理盐水组（44.00 s [41.00-47.00] vs. 52.00 s[50.00-58.00]）。结论：氧美唑啉可缩短鼻甲肥大患者的支气管镜检查时间，缓解鼻通道，减轻粘膜损伤，减轻疼痛。该试验已在chictr.org.cn注册（ChiCTR2300077642）。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical Otolaryngology 医学-耳鼻喉科学

CiteScore

4.00

自引率

4.80%

发文量

106

审稿时长

>12 weeks

期刊介绍： Clinical Otolaryngology is a bimonthly journal devoted to clinically-oriented research papers of the highest scientific standards dealing with: current otorhinolaryngological practice audiology, otology, balance, rhinology, larynx, voice and paediatric ORL head and neck oncology head and neck plastic and reconstructive surgery continuing medical education and ORL training The emphasis is on high quality new work in the clinical field and on fresh, original research. Each issue begins with an editorial expressing the personal opinions of an individual with a particular knowledge of a chosen subject. The main body of each issue is then devoted to original papers carrying important results for those working in the field. In addition, topical review articles are published discussing a particular subject in depth, including not only the opinions of the author but also any controversies surrounding the subject. • Negative/null results In order for research to advance, negative results, which often make a valuable contribution to the field, should be published. However, articles containing negative or null results are frequently not considered for publication or rejected by journals. We welcome papers of this kind, where appropriate and valid power calculations are included that give confidence that a negative result can be relied upon.